Lupin is rationalizing its product portfolio in the US, transitioning from simple oral solid medicines to more complex generics to overcome the impact of price erosion witnessed in the market. In the years to come, the company hopes to have up to 40 per cent of its revenue coming from such medicines in the US market with its planned product pipeline for complex generic medicines in the next two years.
Lupin's transitioning of the portfolio from the simple generic oral solids to complex generics had started with short-acting bronchodilator albuterol. Going ahead, Brovana, which is indicated for chronic obstructive pulmonary disease, will be further strengthened with Spiriva, a long-acting bronchodilator.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
